CRITICAL CARE COVID-19 MANAGEMENT PROTOCOL: CLINICAL CASE
Abstract
One of the principal precepts of bioethics that all students in healthcare are taught in school which is a fundamental principle throughout of medicine, is referred as the Latin phrase “primum non nocere”. This means that, in regard to therapeutic strategies, it is first of all necessary not to harm the patient and for this reason, among the possible treatments, the one that has fewer contraindications should always be privileged.
The current COVID-19 pandemic today counts more than 46 million cases and more than 1 million deaths worldwide.
While the vast majority of the scientific community is working tirelessly on the development of vaccines and control of the application of the results produced by the use of drugs in hospitalized patients, few studies have dealt with issues related to the concepts of prophylaxis and treatment of the early phase of the disease.
Prophylaxis includes strategies capable, on the one hand, of containing the spread of SARS-CoV-2, on the other hand, mitigating the development of the immune system imbalance caused in severe forms of Coronavirus disease. That is why we present the MATH + clinical guidelines, which were created thanks to an international alliance of doctors from around the world and a description of the clinical case when the MATH + clinical guidelines were used.
Medicine is a direction of human activity, which in its charity knows no boundaries, age restrictions, emotions and prohibitions. The doctor everywhere rushes to the rescue neglecting personal. That is why we strive to help all health workers, who are at the Front Line in the fight for the lives of COVID-19 critical patients.
Downloads
References
https://covid19criticalcare.com
https://www.puyadehgani.com/protocollod
https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1808462
https://covid19criticalcare.com/math-hospital-treatment/pdf-translations/
www.flccc.net
World Health Organization. Coronavirus disease 2019 (COVID-19): situation report −54
Mar 14 [cited 2020 sep 7]. https://www. who.int/docs/default-source/coronaviruse/situation-reports /20200314-sitrep-54-covid-19.pdf
Alhazzani W, Moller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with corona- virus disease 2019 (COVID-19) (March 20, 2020 Version). Crit Care Med. 2020;48(6):e440-e469.
https://doi.org/10.1097/CCM.0000000000004363
Cecconi M, Forni G, Mantovani A. Ten things we learned about COVID-19. Intensive Care Med. 2020;46:1590-1593.
https://doi.org/10.1007/s00134-020-06140-0
Li Y, Chen M, Cao H. Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response. Microbes Infect. 2013;15(2):88-95.
https://doi.org/10.1016/j.micinf.2012.10.008
Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036-1045.e9.
https://doi.org/10.1016/j.cell.2020.04.026
Giamarellos-Bouboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992-1000.e3.
https://doi.org/10.1016/j.chom.2020.04.009
Dorward DA, Russell CD, Um IH, et al. Tissue-specific tolerance in fatal COVID-19. medRxiv. 2020.
https://doi.org/10.1101/2020.07.02.20145003
Du L, Kao RY, Zhou Y, et al. Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun. 2007;359:174-179.
https://doi.org/10.1016/j.bbrc.2007.05.092
Yuriditsky E, Horowitz JM, Merchan C, et al. Thromboelastography profiles of critically ill patients with coronavirus disease 2019. Crit Care Med. 2020. DOI:10.1097/CCM.0000000000004471
https://doi.org/10.1097/CCM.0000000000004471
Draghici S, Nguyen TM, Sonna LA, et al. COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases. Nat Rev. 2020.
https://doi.org/10.1101/2020.05.06.20076687
Fadel R, Morrison AR, Vahia A, et al. Early course corticosteroids in hospitalized patients with COVID-19. medRxiv. 2020.
https://doi.org/10.1101/2020.05.04.20074609
Salton F, Confalonieri P, Santus P, et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. medRxiv. 2020.
https://doi.org/10.1101/2020.06.17.20134031
Chroboczek T, Lacoste M, Wackenheim C, et al. Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis. medRxiv. 2020.
https://doi.org/10.1101/2020.05.08.20094755
Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. medRxiv. 2020.
https://doi.org/10.1101/2020.06.17.20133579
Clinical management of COVID-19. Interim guidance. World Health Organization; 2020 May 27 [cited 2020 Oct 7]. https://www.who. int/publications/i/item/clinical-management-of-covid-19 WHO/ 2019-nCoV/clinical/2020.5
Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19 (April 13th 2020, Version). Clin Infect Dis. 2020.
https://doi.org/10.1093/cid/ciaa478
Wilson KC, Chotirmall SH, Bai C, et al. COVID-19: interim guidance on management pending empirical evidence. From an American thoracic society-led international task force (April 3, 2020, Version)
cited 2020 Sep 7. https://www.thoracic.org/covid/covid-19- guidance.pdf
Villar J, Confalonieri M, Pastores SM, et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome (ARDS) caused by COVID-19. Crit Care Expl. 2020;2:e0111.
https://doi.org/10.1097/CCE.0000000000000111
Tang C, Wang Y, Lv H, et al. Caution against corticosteroid-based COVID-19 treatment. Lancet. 2020;395(10239):1759-1760.
https://doi.org/10.1016/S0140-6736(20)30749-2
Russell CD, Millar JE, Bailllie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-475.
https://doi.org/10.1016/S0140-6736(20)30317-2
Liu J, Zheng X, Huang Y, et al. Successful use of methylpredniso- lone for treating severe COVID-19. J Allergy Clin Immunol. 2020;146 (2):325-327.
https://doi.org/10.1016/j.jaci.2020.05.021
RECOVERY Collaborative Group. Effect of dexamethasone in hospi- talized patients with COVID-19-preliminary report. N Engl J Med. 2020.
Li H, Yang SG, Gu L, et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A (H1N1) pdm09 viral pneumonia. Influenza Other Respi Viruses. 2017;11:345-354.
https://doi.org/10.1111/irv.12456
Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids. The Guangzhou experience. Chest. 2006;129: 1441-1452.
https://doi.org/10.1378/chest.129.6.1441
Braude AC, Rebuck AS. Prednisone and methylprednisolone disposition in the lung. Lancet. 1983;322(8357):995-997.
https://doi.org/10.1016/S0140-6736(83)90981-9
Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum DIs. 2002;61:718-722.
https://doi.org/10.1136/ard.61.8.718
Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016;42:15-31.
https://doi.org/10.1016/j.rdc.2015.08.002
Li H, Yang SG, Gu L, et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A (H1N1) pdm09 viral pneumonia. Influenza Other Respi Viruses. 2017;11:345-354.
https://doi.org/10.1111/irv.12456
Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids. The Guangzhou experience. Chest. 2006;129: 1441-1452.
https://doi.org/10.1378/chest.129.6.1441
Braude AC, Rebuck AS. Prednisone and methylprednisolone disposition in the lung. Lancet. 1983;322(8357):995-997.
https://doi.org/10.1016/S0140-6736(83)90981-9
Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum DIs. 2002;61:718-722.
https://doi.org/10.1136/ard.61.8.718
Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016;42:15-31.
https://doi.org/10.1016/j.rdc.2015.08.002
Oakley RH, Cidlowski JA. The biology of the glucocorticoid recep- tor: new signaling mechanisms in health and disease. J Allergy Clin Immunol. 2013;132:1033-1044.
https://doi.org/10.1016/j.jaci.2013.09.007
Marik PE, Vitamin C. An essential "stress hormone" during sepsis. J Thorac Dis. 2020;12(suppl 1):S84-S88.
https://doi.org/10.21037/jtd.2019.12.64
Marik PE. Vitamin C for the treatment of sepsis: the scientific rationale. Pharmacol Therapeut. 2018;189:63-70.
https://doi.org/10.1016/j.pharmthera.2018.04.007
Marik PE. Hydrocortisone, ascorbic acid and thiamine (HAT therapy) for the treatment of sepsis. Focus on ascorbic acid. Nutrients. 2018;10:1762.
https://doi.org/10.3390/nu10111762
Colunga. Biancatelli RM, Berrill M, Marik PE. The antiviral properties of vitamin C. Expert Rev Anti Infect Ther. 2020;18:99-101.
https://doi.org/10.1080/14787210.2020.1706483
Colunga Biancatelli RM, Berrill M, Catravas JD, et al. Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2related disease (COVID-19). Front Immunol. 2020;11:1451.
https://doi.org/10.3389/fimmu.2020.01451
Reiter RJ, Abreu-Gonzalez P, Marik PE, Dominguez-Rodriguez A. Therapeutic algorithm for use of melatonin in patients with COVID-19. Front Med 2020; 7:226.
https://doi.org/10.3389/fmed.2020.00226
Reiter RJ, Sharma R, Ma Q, Dominquez-Rodriguez A, Marik PE, Abreu-Gonzalez P. Melatonin inhibits COVID-19-induced cytokine storm by reversing aerobic glycolysis in immune cells: A mechanistic analysis. Medicine in Drug Discovery 2020; 6:100044.
https://doi.org/10.1016/j.medidd.2020.100044
Zhang R, Wang X, Ni L, Di X, Ma B. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci 2020;250:117583.
https://doi.org/10.1016/j.lfs.2020.117583
May JM, Qu ZC. Ascorbic acid prevents oxidant-induced increases in endothelial permeability. Biofactors. 2011;37:46-50.
https://doi.org/10.1002/biof.134
May JM, Harrison FE. Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal. 2013;19:2068-2083.
https://doi.org/10.1089/ars.2013.5205
Barabutis N, Ingoora V, Marik PE, et al. Hydrocortisone and ascorbic acid synergistically protect and repair lipopolysaccharide-induced pulmonary endothelial barrier dysfunction. Chest. 2017;152:954-962.
https://doi.org/10.1016/j.chest.2017.07.014
Howell AP, Parrett JL, Malcom DR. Impact of high-dose intravenous vitamin C for treatment of sepsis on point-of-care blood glucose readings. J Diabetes Sci Technol. 2019;193229681988963. DOI:10.1177/1932296819889638
https://doi.org/10.1177/1932296819889638
Stephenson E, Hooper MH, Marik PE. Vitamin C and point of care glucose measurements: A retrospective, observational study [Abstract]. Chest. 2018;154(suppl.):255a.
https://doi.org/10.1016/j.chest.2018.08.232
Marik PE. Is intravenous Vitamin C contraindicated in patients with G6PD deficiency? Crit Care. 2019;23:109.
https://doi.org/10.1186/s13054-019-2397-6
Vatsalya V, Li F, Frimodig J, Gala KS, Srivastava S, Kong M. Therapeutic prospects for Th-17 cell immune storm syndrome and neurological symptoms in COVID-19: Thiamine efficacy and safety, In-vitro evidence and pharmacokinetic profile. medRxiv 2020.
https://doi.org/10.1101/2020.08.23.20177501
Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C and Thiamine for the treatment of severe sepsis and septic shock: A retrospective before-after study. Chest 2017; 151:1229-38.158
https://doi.org/10.1016/j.chest.2016.11.036
Iglesias J, Vassallo AV, Patel V, Sullivan JB, Cavanaugh J, Elbaga Y. Outcomes of metabolic resuscitation using ascorbic acid, thiamine, and glucocorticoids in the early treatment of sepsis. Chest 2020; 158:164-74
https://doi.org/10.1016/j.chest.2020.02.049
Collie JT, Greaves RF, Jones OA, et al. Vitamin B1 in critically ill patents: needs and challenges. Clin Chem Lab Med. 2017;55:1652-1668.
https://doi.org/10.1515/cclm-2017-0054
Cruickshank AM, Telfer AB, Shenkin A. Thiamine deficiency in the critically ill. Intensive Care Med. 1988;14:384-387.
https://doi.org/10.1007/BF00262893
Donnino MW, Carney E, Cocchi MN, et al. Thiamine deficiency in critically ill patients with sepsis. J Crit Care. 2010;25:567-581.
https://doi.org/10.1016/j.jcrc.2010.03.003
Donnino MW, Andersen LW, Chase M, et al. Randomized, double-blind, placebo-controlled trial of thiamine as a metabolic resuscitator in septic shock: A pilot study. Crit Care Med. 2016;44:360-367.
https://doi.org/10.1097/CCM.0000000000001572
Crook MA, Sriram K. Thiamine deficiency: the importance of recog- nition and prompt management. Nutrition. 2014;30:953-954.
https://doi.org/10.1016/j.nut.2014.03.003
O'Keeffe ST, Tormey WP, Glasgow R, et al. Thiamine deficiency in hospitalized elderly patients. Gerontology. 1994;40:18-24.
https://doi.org/10.1159/000213570
Pepersack T, Garbusinski J, Robberecht J, et al. Clinical relevance of thiamine status amongst hospitalized elderly patients. Gerontology. 1999;45:91-101.
https://doi.org/10.1159/000022070
Zhang F, Masania J, Anwar A, et al. The uremic toxin oxythiamine causes functional thiamine deficiency in end-stage renal disease by inhibiting transketolase activity. Kidney Int. 2016;90:396-403.
https://doi.org/10.1016/j.kint.2016.03.010
de Andrade JA, Gayer CR, Nogueira NP, et al. The effect of thiamine deficiency on inflammation, oxidative stress and cellular migration in an experimental model of sepsis. J Inflamm. 2014;11:11.
https://doi.org/10.1186/1476-9255-11-11
Beltramo E, Berrone E, Buttiglieri S, et al. Thiamine and benfotia- mine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev. 2004;20: 330-336.
https://doi.org/10.1002/dmrr.470
Hazell AS, Faim S, Wertheimer G, et al. The impact of oxidative stress in thiamine deficiency: A multifactorial targeting issue. Neurochem Int. 2013;62:796-802.
https://doi.org/10.1016/j.neuint.2013.01.009
Lee CY, Jan WC, Tsai PS, Huang CJ. Magnesium sulfate mitigates acute lung injury in endotoxemia rats. JTrauma 2011; 70:1177-85.
https://doi.org/10.1097/TA.0b013e31820ca695
Tan CW, Ho LP, Kalimuddin S, Cherng BP, Teh YE. Cohort study to evaluate effect of vitamin D, magnesium, and vitamin b12 in combination on severe outcome progression in older patients with coronavirus (COVID-19). Nutrition 2020; 80:111017.
https://doi.org/10.1016/j.nut.2020.111017
Peake RW, Godber IM, Maguire D. The effect of magnesium admin- istration on erythrocyte transketolase activity in alcoholic patients treated with thiamine. Scott Med J. 2013;58:139-142.
https://doi.org/10.1177/0036933013496944
Zieve L. Influence of magnesium deficiency on the utilization of thiamine. Ann New York Acad Sci. 1969;162:732-743.
https://doi.org/10.1111/j.1749-6632.1969.tb13005.x
Marik PE, Varon J. Sepsis, delirium and long-term cognitive dys- function: prevention with the combination of vitamin C, hydrocor- tisone and thiamine. Curr Resp Med Rev. 2018;14:23-28.
https://doi.org/10.2174/1573398X14666180430145142
Juel J, Pareek M, Langfrits CS, et al. Anaphylactic shock and cardiac arrest caused by thiamine infusion. BMJ Case Rep. 2013;2013(jul12 1):bcr2013009648-bcr2013009648.
https://doi.org/10.1136/bcr-2013-009648
Wrenn KD, Slovis CM. Is intravenous thiamine safe? Am J Emerg Med. 1992;10:165.
https://doi.org/10.1016/0735-6757(92)90054-2
Trigonis RA, Holt DB, Yuan R, et al. Incidence of venous throm- boembolism in critically ill coronavirus disease 2019 patients receiving prophylactic anticoagulation. Crit Care Med. 2020. DOI:10.1097/CCM.0000000000004472
https://doi.org/10.1097/CCM.0000000000004472
Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospec- tive cohort study. Intensive Care Med. 2020;46:1089-1098.
https://doi.org/10.1007/s00134-020-06062-x
Klok FA, Kruip MJ, van der Meer NJ, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020.
https://doi.org/10.1016/j.thromres.2020.04.041
Dayer MR Coronavirus (2019-nCoV) deactivation via spike glyco- protein shielding by old drugs, bioinformatic study. Preprints. 2020. 60. Kwon PS, Oh H, Kwon SJ, et al. Sulphated polysaccharides effectively inhibit SARS-CoV-2 in vitro. Cell Discov. 2020;6:50.
https://doi.org/10.20944/preprints202005.0020.v1
While D, MacDonald S, Bull T, et al. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis. 2020.
https://doi.org/10.1007/s11239-020-02196-3
Tomasa-Irriguible TM, Martinez-Vega S, Mor-Marco E, et al. Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance! Crit Care. 2020;24:325.
https://doi.org/10.1186/s13054-020-03058-3
Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thromb Haemost. 2020;18:1320-1323.
https://doi.org/10.1111/jth.14871
Freedberg DE, Conigliaro J, Sobieszczyk ME, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. medRxiv. 2020.
https://doi.org/10.1053/j.gastro.2020.05.053
Jehi L, Ji X, Milinovich A, et al. Individualizing risk prediction for positive COVID-19 testing. Results from 11,672 patients. Chest. 2020. DOI:10.1016/j.chest.2020.05.580
https://doi.org/10.1016/j.chest.2020.05.580
Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176-187.e4.
https://doi.org/10.1016/j.cmet.2020.06.015
Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, et al. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care. 2020;24:429.
https://doi.org/10.1186/s13054-020-03154-4
Merzon E, Tworowski D, Gorohovski A, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infec- tion: an Israeli population-based study. Faseb J. 2020.
https://doi.org/10.1101/2020.07.01.20144329
Rhodes JM, Subramanian S, Laird E, et al. Editorial: low population mortality from COVID-19 in countries south of 35 degrees north - supports vitamin D as a factor determining severity. Aliment Pharmacol Ther 2020;(in press).
https://doi.org/10.1111/apt.15777
Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Resp Med 2018; 6:691-8.
https://doi.org/10.1016/S2213-2600(18)30177-2
- Gupta A, Madhavan MV, Poterucha TJ, DeFilippis EM, Hennessey JA. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Research Square 2020.
https://doi.org/10.21203/rs.3.rs-56210/v1
-Kow CS, Hasan SS. Meta-analysis of effectiveness of statins in patients with severe COVID-19. Am J Cardiol 2020.
https://doi.org/10.1016/j.amjcard.2020.08.004
-Tan WY, Young BE, Lye DC, Chew DE, Dalan r. Statin use is assocaited with lower disease severity in COVID-19 infection. Nature Research 2020
https://doi.org/10.1038/s41598-020-74492-0
Daneshkhah A, Eshein A, Subramanian H. The role of vitamin D in suppressing cytokine storm of COVID-19 patients and associated mortality. medRxiv. 2020.
https://doi.org/10.1101/2020.04.08.20058578
Jiang P, Lv Q, Lai T. Does hypomagnesemia impact on the outcome of patients admitted to the intensive care unit? A systematic review and meta-analysis. Shock. 2019;47(3):288-295.
Abstract views: 1066 PDF Downloads: 835